Aphria will issue CAD $193 million in shares to Scythian and assume USD $1 million in aggregate liabilities of the Target Corporations owing to Scythian (the “Consideration”) resulting in Scythian having well over $200 million in cash and marketable securities on hand.
The substantial liquidity provided by the Transaction will enable additional potential transactions that underpin Scythian’s strategic transformation towards enhancing its global cannabis foundation.
About Scythian Biosciences Corp.
Scythian is an international cannabis company with a focus on the world’s leading markets outside of Canada. Its fast tracked growth has come through a number of strategic investments and regional partnerships in cultivation, distribution and branded products across Europe, United States, South America and the Caribbean. These significant endeavors complement the company’s R&D partnerships with some of the world’s leading universities. It is this comprehensive approach that is positioning Scythian as a future global frontrunner in the medical cannabis industry.
News 
Market Data 
Discover 
